2篇
您的检索式：作者名="GUAN FaMing"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Experimental and numerical study on instability structure of the supersonic mixing layer(M_c = 0.5)显示文摘The parameters of instability wave of supersonic mixing layer(Mc=0.5,M1=3.5/M2=1.4) are measured by flow visualization and calculated by means of two-dimensional direct numerical simulaitons of the compressible Navier-Stokes equations.In both cases of the mixing layer with harmonic disturbance or not,the comparative results indicate that the wavelength of the two-dimensional wave is equal to the vortex spacing in the streamwise direction because the difference between them is less than 1%.However,the measured convective velocity of the large-scale structure deviates from the theoretical isentropic prediction about 10%.Here the measured value confirms that Mc,2 | YANG WuBing ZHUANG FengGan SHEN Qing GUAN FaMing WANG Qiang YI ShiHe ZHAO YuXin HE Lin TIAN LiFeng | 2009 | Science China(Physics,Mechanics & Astronomy)2009，52，10： | 2 |
| 2 | The benefits of PCSK9 inhibitors in patients with acute coronary syndrome:a systematic review and meta-analysis显示文摘Background:Proprotein convertase subtilisin/kexin 9(PSCK9)inhibitors have been beneficial for many patients with hyperlipidemia.The objective of this study was to investigate the benefit of PSCK9 inhibitors in patients with acute coronary syndrome(ACS).Methods:We systematically searched PubMed,EMBASE,and Cochrane Clinical Trials(published before January 2023;no language restriction)to compare the treatment of patients with ACS using PCSK9 inhibitors and placebo.The primary end points were major adverse cardiovascular events,nonfatal myocardial infarction,cardiogenic death,stroke,hospitalization for recurrent ACS,and coronary revascularization.Fixed-or random-effects models were used to assess the aggregated data.Results:Of the 1686 identified studies,5 were eligible and included in our analysis(of a total of 38,005 participants,18,609 cases were placed in the PCSK9 inhibitor treatment group and 19,396 cases in the placebo group).Compared with the placebo group,PCSK9 inhibitors significantly reduced the major adverse cardiovascular events(odds ratio[OR]:0.83;95%confidence interval[CI]:0.77–0.88;P<0.00001)for patients following ACS.The incidence of nonfatal myocardial infarction(relative risk:0.80;95%CI:0.74–0.87;P<0.00001),cardiovascular death(OR:0.96;95%CI:0.83–1.10;P=0.56),stroke(OR:0.74;95%CI:0.63–0.88;P=0.0007),hospitalization for recurrent ACS(OR:0.57;95%CI:0.40–0.83;P=0.003),or coronary revascularization(OR:0.82;95%CI:0.76–0.88;P<0.00001)all demonstrated a significant decrease in the comparison between the 2 groups.Conclusion:This meta-analysis demonstrated that treatment with PCSK9 inhibitors in patients with ACS reduced the probability of multiple cardiovascular events and improved patient prognosis. | Guanzhao Zhang Shuting Chang Faming Zhao Xiangfeng Guan Zifan Nie Wenhao Liu Bo Li | 2024 | Emergency and Critical Care Medicine2024，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员